Partnering for Success
We believe that through our collective efforts and experience, we can overcome the challenges associated with devastating diseases including within oncology, rare disease and neuroscience. Collaboration and partnership is fundamental to our strategy at Ipsen for building a sustainable pipeline, and to our core belief that together, we can do more for patients and for society.
We work with our partners to define a shared vision to unlock the full potential of their products, achieving mutual success for our partners and Ipsen. We have the capabilities and expertise of a large pharmaceutical company, but we’re the right size to make your medicine a priority. Our team has an outstanding partnership track record successfully progressing partnered products through global development and maximizing their value by expanding indications and opening new markets. Working with Ipsen, you will find that your innovation is a top priority for us; we have the financial resources to invest for the long-term; and our size allows us to be flexible and creative in transactions.
Patients need us. Together, let’s make a difference.
We have a strong track record of success:
At Ipsen we translate these collaborations into value for both partners, demonstrated through our Global commercial success which boasts a balanced focus on commercial territories across North America (34%), Western Europe (around 30%) and Rest of World (more than 30%).
Our relationships speak for themselves:
Hear what our partners have to say with this word from Nicholas Waters, CEO IRLAB:
Ipsen and IRICoR’s agreement for a discovery-stage oncology target is one in which “everyone wins”.
Together with Exelixis we have engaged in the development of a large number of indications to maximize the potential of Cabometyx.
How We Work
Every partnership is unique and requires a tailored approach to ensure success. Our goal is to foster solutions that deliver new therapies through flexible, innovative agreements that maximize the potential of the science.
We build relationships based on mutual goals
Successful partnerships start with a clear and transparent process that ultimately leads to developing common goals. We view every partnership opportunity as unique and our partnering process is customized to your asset and what you are looking for in a partnership with Ipsen.
We work together with you
We match you with a specialist with expertise in your area to explore the partnership options and introduce you to the value Ipsen can bring. Our approach is collaborative to ensure a mutually beneficial structure.
We believe in collaboration and transparency
Challenges are inevitable. At Ipsen, you will have a dedicated alliance manager who is transparent throughout the partnership process and who stays fully engaged with you along the way.
Our Focus Areas
We focus on underserved, high unmet need oncology indications and life cycle management programs in additional indications to expand benefits and market potential. Our external innovation focus is on solid and hematologic malignancies. This includes niche tumors and patient selection biomarker segments in broader indications in preclinical to marketed products. Oncology is a key driver of our commercial success and we are a top 14 oncology company globally.
We have proven capabilities and a patient-centric model to serve unmet needs in rare disease indications, including a portfolio approach to treat fibrodysplasia ossificans progressiva (FOP) with two potential first-in-class assets. Beyond our world first global Phase III programs in this ultra-rare disease we also are proud to drive greater understanding through the first Natural History Study in FOP. We have expanded our focus in a broad range of rare disease areas, including established and emerging modalities and gene-based therapies at all stages of development.
We have true bench to bedside expertise within R&D. We are developing novel and long-acting neurotoxins for aesthetic and treatment indications which entered first patient treatment in the clinic in Q1 2021. Our external innovation strategy includes rare neurodegenerative and rare neuroinflammatory and movement disorders and other adjacencies to disparate and future novel toxins.
Connect with Us
“Patients are the focus of everything we do at Ipsen. Advancing research and developing treatments that will improve and extend the lives of people living with conditions like cancer and rare diseases is our goal. Working in partnership is a mindset, a value and a belief rooted firmly in Ipsen’s development teams.”
Christelle Huguet SVP, Head of Research, External Innovation and Early Development